Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials

Autor: Mark R Lankisch, Marie Paule Dain, Stefano Del Prato, David R. Owens, Peter R. Mullins
Rok vydání: 2016
Předmět:
Blood Glucose
Male
Insulin glulisine
Time Factors
Endocrinology
Diabetes and Metabolism
Insulin Glargine
Type 2 diabetes
Weight Gain
Body Mass Index
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Risk Factors
Basal-plus
HbA1c
Hypoglycemia
Insulin
030212 general & internal medicine
Randomized Controlled Trials as Topic
education.field_of_study
Nutrition and Dietetics
Age Factors
Middle Aged
Diabetes and Metabolism
Treatment Outcome
Drug Therapy
Combination
Female
Family Practice
medicine.drug
medicine.medical_specialty
Population
030209 endocrinology & metabolism
Drug Administration Schedule
03 medical and health sciences
Internal medicine
Diabetes mellitus
medicine
Internal Medicine
Humans
Hypoglycemic Agents
education
Aged
Glycated Hemoglobin
business.industry
medicine.disease
Regimen
Diabetes Mellitus
Type 2
chemistry
Basal (medicine)
Glycated hemoglobin
business
Biomarkers
Zdroj: Primary Care Diabetes. 10(1):51-59
ISSN: 1751-9918
DOI: 10.1016/j.pcd.2015.05.003
Popis: AimsTo evaluate the efficacy and safety of adding a single bolus dose of insulin glulisine to basal insulin (‘basal-plus’) in persons with type 2 diabetes.MethodsData from patients with poor glycemic control on oral antihyperglycemic drugs who were initiated on a ‘basal-plus’ regimen for up to 6 months were pooled from four randomized, multicenter studies. Glycated hemoglobin (HbA1c), fasting blood glucose, postprandial glucose (PPG), insulin dose and demographics were measured at baseline and end of study.Results711 patients with a mean age of 59.9 years and a mean duration of diabetes of 11.0 years were included in the analysis population. A ‘basal-plus’ regimen was associated with significant decreases in HbA1c and PPG at 6 months, an increase in glargine and glulisine doses and small, but statistically significant, changes in body weight and BMI in all patient subsets. The proportion of patients with HbA1c
Databáze: OpenAIRE
Externí odkaz: